2 active not recruiting, 1 recruiting. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Metastatic Uveal Melanoma: new trials by email Literature Review of Metastatic Uveal Melanoma trials Research Report on Metastatic Uveal Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma RP2, Ipilimumab, Nivolumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Recruiting | Replimune, Inc. | 280 | 2024-12-17 | 2026-04-02 |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma IDE196, Crizotinib, Pembrolizumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Active not recruiting | IDEAYA Biosciences | 420 | 2023-10-31 | 2026-02-17 |
| An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) - Metastatic Ocular Melanoma, Metastatic Uveal Melanoma | Phase 3 | Active not recruiting | Delcath Systems Inc. | 30 | 2022-06-10 | 2023-12-21 |
Uveal Melanoma (3) · Melanoma (2) · Neoplasm Metastasis (1)
Eye Diseases (3) · Eye Neoplasms (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3) · Nevi and Melanomas (3) · Uveal Diseases (3) · Uveal Neoplasms (3) · Skin Diseases (2) · Skin Neoplasms (2) · Skin and Connective Tissue Diseases (2)
Ipilimumab (2) · Nivolumab (2) · Crizotinib (1) · Dacarbazine (1) · Melphalan (1) · pembrolizumab (1)
Delcath Systems Inc. (1) · IDEAYA Biosciences (1) · Replimune, Inc. (1)
United States (3) · Australia (2) · United Kingdom (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Switzerland (1)
Hetal Patel, MD, MSHS, CHCQM (1) · Rahul Marpadga, MD MPH (1)